Laurus Labs Limited (NSE:LAURUSLABS) — Market Cap & Net Worth

$6.43 Billion USD  · Rs594.36 Billion INR  · Rank #3039

Market Cap & Net Worth: Laurus Labs Limited (LAURUSLABS)

Laurus Labs Limited (NSE:LAURUSLABS) has a market capitalization of $6.43 Billion (Rs594.36 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #3039 globally and #136 in its home market, demonstrating a 0.44% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Laurus Labs Limited's stock price Rs1100.95 by its total outstanding shares 539856582 (539.86 Million). Analyse Laurus Labs Limited cash conversion from operations to see how efficiently the company converts income to cash.

Laurus Labs Limited Market Cap History: 2016 to 2026

Laurus Labs Limited's market capitalization history from 2016 to 2026. Data shows growth from $526.17 Million to $6.43 Billion (30.64% CAGR).

Index Memberships

Laurus Labs Limited is a constituent of 8 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NIFTY PHARMA
CNXPHARMA
$86.64 Billion 7.42% #7 of 20
NIFTY SMALLCAP 100
NIFSMCP100
$190.91 Billion 3.37% #3 of 100
NIFTY 500
NIFTY500
$3.11 Trillion 0.21% #125 of 500
NIFTY HEALTHCARE
NIFTYHEALTHCARE
$102.93 Billion 6.24% #9 of 20
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
$1.11 Trillion 0.58% #56 of 400
NIFTY TOTAL MARKET
NIFTYTOTALMKT
$3.20 Trillion 0.20% #124 of 750
NIFTY SMALLCAP 250
NISM250
$375.15 Billion 1.71% #3 of 250
NIFTY SMALLCAP 50
NISM50
$112.36 Billion 5.72% #3 of 50

Weight: Laurus Labs Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Laurus Labs Limited Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Laurus Labs Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.12x

Laurus Labs Limited's market cap is 0.12 times its annual revenue

Industry average: 1.04x Lower than industry average

Latest Price to Earnings (P/E) Ratio

1.81x

Laurus Labs Limited's market cap is 1.81 times its annual earnings

Industry average: 8.30x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $526.17 Million $17.78 Billion $1.34 Billion 0.03x 0.39x
2017 $595.49 Million $19.05 Billion $1.90 Billion 0.03x 0.31x
2018 $417.69 Million $20.56 Billion $1.68 Billion 0.02x 0.25x
2019 $406.26 Million $22.92 Billion $937.64 Million 0.02x 0.43x
2020 $2.03 Billion $28.32 Billion $2.55 Billion 0.07x 0.80x
2021 $3.11 Billion $48.14 Billion $9.84 Billion 0.06x 0.32x
2022 $2.18 Billion $49.36 Billion $8.28 Billion 0.04x 0.26x
2023 $2.51 Billion $60.41 Billion $7.90 Billion 0.04x 0.32x
2024 $3.52 Billion $50.41 Billion $1.61 Billion 0.07x 2.19x
2025 $6.47 Billion $55.54 Billion $3.58 Billion 0.12x 1.81x

Competitor Companies of LAURUSLABS by Market Capitalization

Companies near Laurus Labs Limited in the global market cap rankings as of May 4, 2026.

Key companies related to Laurus Labs Limited by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
  • Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#499 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#525 Zoetis Inc NYSE:ZTS $50.31 Billion $114.16
#526 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $50.29 Billion CN¥53.88
#572 GALDERMA GROUP AG NYSE:GALDY $45.88 Billion $42.15

Laurus Labs Limited Historical Marketcap From 2016 to 2026

Between 2016 and today, Laurus Labs Limited's market cap moved from $526.17 Million to $ 6.43 Billion, with a yearly change of 30.64%.

Year Market Cap Change (%)
2026 Rs6.43 Billion -0.64%
2025 Rs6.47 Billion +83.84%
2024 Rs3.52 Billion +40.34%
2023 Rs2.51 Billion +15.19%
2022 Rs2.18 Billion -30.10%
2021 Rs3.11 Billion +53.28%
2020 Rs2.03 Billion +400.06%
2019 Rs406.26 Million -2.74%
2018 Rs417.69 Million -29.86%
2017 Rs595.49 Million +13.18%
2016 Rs526.17 Million --

End of Day Market Cap According to Different Sources

On May 4th, 2026 the market cap of Laurus Labs Limited was reported to be:

Source Market Cap
Yahoo Finance $6.43 Billion USD
MoneyControl $6.43 Billion USD
MarketWatch $6.43 Billion USD
marketcap.company $6.43 Billion USD
Reuters $6.43 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Laurus Labs Limited

NSE:LAURUSLABS India Drug Manufacturers - Specialty & Generic
Market Cap
$6.43 Billion
Rs594.36 Billion INR
Market Cap Rank
#3039 Global
#136 in India
Share Price
Rs1100.95
Change (1 day)
-0.47%
52-Week Range
Rs586.75 - Rs1135.75
All Time High
Rs1135.75
About

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more